Sinopharm Group Co. Ltd. (SEHK: 01099) has released an announcement regarding its subsidiary, China National Medical Device Co., Ltd. (Sinopharm Devices).
For the nine months ended September 30, 2026, the subsidiary recorded operating revenue of RMB 55.262 billion, representing a year-on-year increase of 1.04%.
Operating profit came in at RMB 856 million, down 11.07% compared to the same period last year.
Total comprehensive income attributable to owners of the parent company amounted to RMB 391 million, a year-on-year decrease of 1.03%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments